Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Accounts Payables (2016 - 2025)

UroGen Pharma (URGN) has disclosed Accounts Payables for 10 consecutive years, with $27.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables rose 1.04% year-over-year to $27.7 million, compared with a TTM value of $27.7 million through Dec 2025, up 1.04%, and an annual FY2025 reading of $27.7 million, up 1.04% over the prior year.
  • Accounts Payables was $27.7 million for Q4 2025 at UroGen Pharma, up from $10.3 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $31.0 million in Q2 2025 and bottomed at $2.5 million in Q2 2022.
  • Average Accounts Payables over 5 years is $13.4 million, with a median of $10.7 million recorded in 2021.
  • The sharpest move saw Accounts Payables crashed 76.99% in 2022, then soared 567.6% in 2023.
  • Year by year, Accounts Payables stood at $12.1 million in 2021, then tumbled by 54.33% to $5.5 million in 2022, then skyrocketed by 199.22% to $16.5 million in 2023, then soared by 65.87% to $27.4 million in 2024, then rose by 1.04% to $27.7 million in 2025.
  • Business Quant data shows Accounts Payables for URGN at $27.7 million in Q4 2025, $10.3 million in Q3 2025, and $31.0 million in Q2 2025.